How is metformin taken?

Forms and strengths
FormStrengths as labelledSource
Immediate-release (IR) tablet500 mg, 850 mg and 1000 mg tablets1
Extended-release (ER) tablet500 mg and 1000 mg2
Oral solution500 mg per 5 mL (100 mg/mL), in a 473 mL bottle3

The immediate-release tablet label starts adults on 500 mg orally twice a day or 850 mg once a day, given with meals, and raises the dose by 500 mg weekly or 850 mg every 2 weeks on the basis of glycemic control and tolerability, up to a maximum of 2550 mg a day in divided doses.1

Forms and strengths

The table is set at the top of the page

The tablet and extended-release tablet labels are both for oral use,12 and a search of DailyMed and PubMed found no injection or powder to mix.

Starting dose, steps and maximum

For adults, the IR label raises the dose by 500 mg weekly or 850 mg every 2 weeks on the basis of glycemic control and tolerability, and says doses above 2000 mg may be better tolerated given 3 times a day with meals.1 Its patient information says to take the tablets with meals, to help lessen an upset stomach side effect, and to swallow them whole.1

For pediatric patients 10 years of age and older, the same label starts at 500 mg twice a day with meals, steps by 500 mg weekly on the basis of glycemic control and tolerability, and stops at 2000 mg a day in divided doses twice daily.1 For adults, the oral solution label gives the same steps by volume, 500 mg (5 mL) weekly or 850 mg (8.5 mL) every 2 weeks, up to 2,550 mg (25.5 mL) a day, and for pediatric patients 10 years of age and older it steps by 500 mg (5 mL) weekly up to 2,000 mg (20 mL) a day.3

Extended-release tablets

The ER label starts at 500 mg once daily with the evening meal, raised by 500 mg weekly on the basis of glycemic control and tolerability to a maximum of 2000 mg once daily, also with the evening meal.2 It says to swallow the tablets whole and never crush, cut or chew them.2 The ER label says patients on IR tablets may be switched to ER once daily at the same total daily dose, up to 2000 mg once daily.2

Doses in named trials

TrialDose and schedulePeopleLength
Diabetes Prevention Program (Diabetes Prevention Program Research Group, 2002)4850 mg once a day, increased to 850 mg twice daily at one month unless gastrointestinal symptoms warranted a longer titration period, against placebo or a lifestyle-modification program3234 nondiabetic people with elevated fasting and post-load plasma glucoseAverage follow-up of 2.8 years
MASTERS (Walton, 2019)51,700 mg a day, against placeboHealthy women and men aged 65 and older: 46 on metformin, 48 on placebo14 weeks of supervised resistance training
HOME trial, vitamin B-12 analysis (de Jager, 2010)6850 mg three times a day, against placebo390 patients aged 30-80 years with type 2 diabetes treated with insulin4.3 years
Aerobic training trial (Konopka, 2019)7500 mg/day in the first week, increased by 500 mg each week to 2000 mg/day (1,000 mg twice daily) by week 4, against placebo; the maximum was 1,500 mg/day in 5 participants who weighed under 75 kg, and the dose was decreased from 2,000 to 1,500 mg/day in 11 participants who reported gastrointestinal discomfort (3 on placebo, 8 on metformin)Older adults (62 ± 1 years) with at least one risk factor for type 2 diabetes: 27 on metformin, 26 on placebo12 weeks of aerobic exercise training
UKPDS 34 (UK Prospective Diabetes Study Group, 1998)8Not stated in the summary; metformin against conventional policy753 overweight patients with type 2 diabetes, 342 on metformin and 411 on conventional policyMedian 10.7 years

Weight loss, cycles and logged doses

The IR label's indication is type 2 diabetes in adults and children 10 and older.1 A search of the DailyMed labels found no weight-loss or longevity dose. No Milligram log figure for metformin can be reported here.

Storage

The IR tablet label gives 20° to 25°C, with excursions permitted to 15° to 30°C.1 The ER label gives 20° to 25°C, says to avoid excessive heat and humidity, protect from light and moisture, and keep the container tightly closed.2 The oral solution label gives 20° to 25°C.3 A search of DailyMed, PubMed and ClinicalTrials.gov found no stability data for any crushed, mixed or diluted form.

Frequently asked questions

What does the IR label say about contrast imaging?

It says to stop metformin at the time of, or before, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m2, in patients with a history of liver disease, alcoholism or heart failure, or in patients who will be given intra-arterial iodinated contrast, then to re-evaluate eGFR 48 hours after the procedure and restart if renal function is stable.1

Which drugs does the IR label say reduce metformin clearance?

The label gives ranolazine, vandetanib, dolutegravir and cimetidine as examples of drugs that reduce metformin clearance, and says such drugs may increase the accumulation of metformin.1

References

  1. DailyMed (US NLM). METFORMIN HYDROCHLORIDE TABLETS. These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE TABLETS. METFORMIN HYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1995. 2026. dailymed.nlm.nih.gov
  2. DailyMed (US NLM). These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS . METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U. 2026. dailymed.nlm.nih.gov
  3. DailyMed (US NLM). These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE ORAL SOLUTION safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE ORAL SOLUTION . METFORMIN HYDROCHLORIDE oral solution Initial U.S. Approval: 1995. 2026. dailymed.nlm.nih.gov
  4. PubMed Central. REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE INTERVENTION OR METFORMIN. pmc.ncbi.nlm.nih.gov
  5. PubMed Central. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double‐blind, placebo‐controlled, multicenter trial: The MASTERS trial. 2019. pmc.ncbi.nlm.nih.gov
  6. PubMed Central. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. 2010. pmc.ncbi.nlm.nih.gov
  7. PubMed Central. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. 2018. pmc.ncbi.nlm.nih.gov
  8. Lancet. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. 1998. pubmed.ncbi.nlm.nih.gov